Clinical Trials
8 trialsNCT06764771 2026-06-03
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
NCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT04349267 2025-12-17
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03693612 2024-08-28
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Phase 1/2 Completed
NCT02599324 2023-11-18
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Pharmacyclics LLC.
Phase 1/2 Completed
NCT03319459 2021-11-22
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT00622674 2017-12-02
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00101348 2014-06-11
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed